{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T21:04:42Z","timestamp":1775423082706,"version":"3.50.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clml.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T05:39:13Z","timestamp":1708580353000},"page":"491-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024"],"prefix":"10.1016","volume":"24","author":[{"given":"Andrew","family":"Ip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Della Pia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-6522","authenticated-orcid":false,"given":"Andre H.","family":"Goy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2024.02.010_bib0001","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/bloodadvances.2021005715","article-title":"Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes","volume":"6","author":"Castellino","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15170","article-title":"Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)","volume":"181","author":"Smith","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0004","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0005","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.02.010_bib0006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/bjh.15643","article-title":"Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network . Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death","volume":"185","author":"Visco","year":"2019","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2024.02.010_bib0007","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","article-title":"Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy","volume":"5","author":"Bond","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.02.010_bib0008","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.02.010_bib0009","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2024.02.010_bib0011","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.02.010_bib0012","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","article-title":"Long-term outcomes with ibrutinib treatment for patients with relapsed\/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up","volume":"6","author":"Dreyling","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0013","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.02.010_bib0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.18519","article-title":"Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study","volume":"202","author":"Hess","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.02.010_bib0066","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0106","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/bjh.15518","article-title":"The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy","volume":"183","author":"Holte","year":"2018","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.clml.2024.02.010_bib0107","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD","volume":"118","author":"Mato","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.clml.2024.02.010_bib0108","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.02.010_bib0024","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.010_bib0027","first-page":"140","article-title":"Efficacy and safety of Ib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0068","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2024.02.010_bib0071","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood.2019852368","article-title":"Acalabrutinib for mantle cell lymphoma","volume":"133","author":"Witzig","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0072","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet. Haematol"},{"issue":"15","key":"10.1016\/j.clml.2024.02.010_bib0032","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/bloodadvances.2023009744","article-title":"Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL","volume":"7","author":"Tisi","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2024.02.010_bib0073","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1080\/10428194.2023.2259528","article-title":"Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Ip","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.clml.2024.02.010_bib0076","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.02.010_bib0109","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jha2.549","article-title":"Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis","volume":"3","author":"Le Bris","year":"2022","journal-title":"EJHaem"},{"issue":"11","key":"10.1016\/j.clml.2024.02.010_bib0110","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.2020006923","article-title":"Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study","volume":"137","author":"Khan","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.02.010_bib0065","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.02.010_bib0077","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1200\/JCO.2006.08.4251","article-title":"Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature","volume":"25","author":"Salaverria","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0078","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2024.02.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-023-03676-6","article-title":"Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas","author":"de Haan","year":"2023","journal-title":"Virchows Archiv"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153283","article-title":"Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma","volume":"132","author":"Yi","year":"2022","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.clml.2024.02.010_bib0015","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","article-title":"Smoldering mantle cell lymphoma","volume":"36","author":"Ye","year":"2017","journal-title":"J Exp Clin Cancer Res: CR"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0019","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.22.01780","article-title":"High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the european mantle cell lymphoma network","volume":"41","author":"Hermine","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.02.010_bib0020","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.02.010_bib0021","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study","volume":"42","author":"Sarkozy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.02.010_bib0022","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.439.439","article-title":"R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma","volume":"118","author":"Kluin-Nelemans","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0023","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplantation"},{"key":"10.1016\/j.clml.2024.02.010_bib0025","article-title":"First-line autologous stem cell transplantation for mantle cell lymphoma: a systematic analysis and treatment recommendation","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0026","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/bmt.2013.56","article-title":"Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?","volume":"48","author":"Chaudhary","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.02.010_bib0028","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","volume":"19","author":"Robak","year":"2018","journal-title":"The Lancet. Oncology"},{"issue":"9873","key":"10.1016\/j.clml.2024.02.010_bib0029","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.02.010_bib0030","first-page":"39","article-title":"ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) \u00b1 lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS","author":"Smith","year":"2021","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0031","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","article-title":"Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi","volume":"4","author":"Visco","year":"2017","journal-title":"The Lancet. Haematology"},{"issue":"23","key":"10.1016\/j.clml.2024.02.010_bib0033","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.3390\/cancers13236089","article-title":"Rituximab and bendamustine (BR) compared with rituximab, bendamustine, and cytarabine (R-BAC) in previously untreated elderly patients with mantle cell lymphoma","volume":"13","author":"Bega","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2024.02.010_bib0034","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/bloodadvances.2019001355","article-title":"Rituximab\/bendamustine and rituximab\/cytarabine induction therapy for transplant-eligible mantle cell lymphoma","volume":"4","author":"Merryman","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.clml.2024.02.010_bib0035","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0036","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(21)00638-0","article-title":"Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial","volume":"23","author":"Wang","year":"2022","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.clml.2024.02.010_bib0037","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1182\/blood-2021-153390","article-title":"IbPlusRituximabandVenetoclax(IRV)FollowedByRisk-Strati edObservationorShortCourse R-Hypercvad\/MTXinYoungPatientswithPreviouslyUntreatedMantleCellLymphoma-Phase-IIWindow-2 ClinicalTrial","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2024.02.010_bib0038","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.02.010_bib0039","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.02.010_bib0041","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hon.3163_99","article-title":"Acalabrutinib with rituximab as first-line therapy for older patients with mantle cell lymphoma\u2014a phase ii clinical trial","volume":"41","author":"Jain","year":"2023","journal-title":"Hematol Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.02.010_bib0042","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1182\/bloodadvances.2023010606","article-title":"Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma","volume":"7","author":"Yamshon","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2024.02.010_bib0043","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0044","doi-asserted-by":"crossref","first-page":"553","DOI":"10.7150\/jca.51959","article-title":"Minimal residual disease and survival outcomes in patients with mantle cell lymphoma: a systematic review and meta-analysis","volume":"12","author":"Zhou","year":"2021","journal-title":"J Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.02.010_bib0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s11864-023-01102-2","article-title":"Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma","volume":"24","author":"Wu","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0046","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.2021014270","article-title":"Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma","volume":"140","author":"Ferrero","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.02.010_bib0047","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0048","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0049","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3324\/haematol.2020.274803","article-title":"Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study","volume":"107","author":"Rule","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.02.010_bib0050","article-title":"Predictive value of minimal residual disease for efficacy of rituximab maintenance in mantle cell lymphoma: results from the european mantle cell lymphoma elderly trial","author":"Hoster","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.02.010_bib0051","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/bjh.16567","article-title":"Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial","volume":"190","author":"Doorduijn","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.02.010_bib0052","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ajh.25783","article-title":"Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB\/Alliance 50403","volume":"95","author":"Kaplan","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0053","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2352-3026(20)30358-6","article-title":"Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial","volume":"8","author":"Ladetto","year":"2021","journal-title":"The Lancet. Haematology"},{"issue":"23","key":"10.1016\/j.clml.2024.02.010_bib0054","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.1182\/bloodadvances.2023011271","article-title":"Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma","volume":"7","author":"Karmali","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.clml.2024.02.010_bib0055","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.02.010_bib0056","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2024.02.010_bib0057","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.clml.2024.02.010_bib0058","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.02.010_bib0059","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10121","key":"10.1016\/j.clml.2024.02.010_bib0060","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0061","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2024.02.010_bib0062","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","article-title":"Treatment of Patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10277","key":"10.1016\/j.clml.2024.02.010_bib0063","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clml.2024.02.010_bib0064","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.02.010_bib0067","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.02.010_bib0069","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet. Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet. Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.02.010_bib0074","first-page":"142","article-title":"A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma","volume":"738","author":"Kumar","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.02.010_bib0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41408-023-00927-2","article-title":"Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma","volume":"13","author":"Jain","year":"2023","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.clml.2024.02.010_bib0079","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","article-title":"Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors","volume":"7","author":"Qi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.02.010_bib0081","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8262787","article-title":"Outcomes among patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States: a real-world electronic medical records study","author":"Hess","year":"2022","journal-title":"Adv Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0082","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.02.010_bib0083","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0084","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2024.02.010_bib0085","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.02.010_bib0086","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood-2021-147563","article-title":"Brexucabtagene autoleucel for relapsed\/refractory mantle cell lymphoma: real world experience from the US lymphoma CAR T consortium","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0087","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0088","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2021014892","article-title":"Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia","volume":"140","author":"Frey","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.02.010_bib0089","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase i, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.clml.2024.02.010_bib0090","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2020008727","article-title":"Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2024.02.010_bib0091","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood-2023-191921","article-title":"Ibrutinib combined with venetoclax in patients with relapsed\/refractory mantle cell lymphoma: priumary analysis results from the randomized phase 3 Sympatico study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.02.010_bib0092","doi-asserted-by":"crossref","first-page":"9325","DOI":"10.1182\/blood-2022-169664","article-title":"A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (Patients) with Non-Hodgkin Lymphoma (NHL) or Waldenstr\u00f6m Macroglobulinemia (WM): Preliminary Data","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0093","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clml.2024.02.010_bib0094","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-136158","article-title":"Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001","volume":"136","author":"Palomba","year":"2020","journal-title":"Blood"},{"issue":"10254","key":"10.1016\/j.clml.2024.02.010_bib0095","first-page":"8839","article-title":"Lisocabtagene maraleucel (liso-cel) in r\/r MCL: primary analysis results from the mcl cohort of the single-arm, multicenter, seamless design transcend NHL 001 study","volume":"396","author":"Wang","year":"2023","journal-title":"ICML"},{"issue":"21","key":"10.1016\/j.clml.2024.02.010_bib0096","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia [published correction appears in Blood Adv","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2024.02.010_bib0097","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"T-cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: phase II TARMAC study","volume":"143","author":"Minson","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.02.010_bib0098","first-page":"529","article-title":"Mosunetuzumab, the first bispecific approved for follicular lymphoma","volume":"21","author":"Budde","year":"2023","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0099","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.02.010_bib0100","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-157777","article-title":"Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma","author":"Phillips","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0101","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-023-00942-3","article-title":"Evolving treatment patterns and improved outcomes in relapsed\/refractory mantle cell lymphoma: a prospective cohort study","volume":"13","author":"Bock","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.02.010_bib0102","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: a British Society for Haematology Guideline","volume":"204","author":"Eyre","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.02.010_bib0103","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy","volume":"13","author":"Marangon","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.clml.2024.02.010_bib0104","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","volume":"56","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400082X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400082X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:47:38Z","timestamp":1729856858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400082X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":110,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S215226502400082X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}